<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00660257</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-PanFlu-1002</org_study_id>
    <nct_id>NCT00660257</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine</brief_title>
  <official_title>Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza (H5N1)Vaccine in Two-Dose Primed Healthy Adults: A Single Center, Non-Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center, non-randomized clinical trial in two-dose primed healthy adults to evaluate
      the safety and immunogenicity of a booster dose of an inactivated pandemic influenza (H5N1)
      vaccine (whole-virion, aluminium-adjuvanted).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HI antibody Neutralization antibody</measure>
    <time_frame>15 and 30 days after the booster dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>local adverse reactions systemic adverse reactions temperature</measure>
    <time_frame>3 days after booster dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Pandemic Influenza Vaccine</condition>
  <condition>Prevention</condition>
  <condition>Pandemic Influenza</condition>
  <arm_group>
    <arm_group_label>No.1: 1.25 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No.2: 2.5 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No.3: 5.0 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No. 4: 10 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pandemic influenza vaccine (H5N1 strain NIBRG-14)</intervention_name>
    <description>pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection</description>
    <arm_group_label>No.1: 1.25 ug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pandemic influenza vaccine (H5N1 strain NIBRG-14)</intervention_name>
    <description>pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 2.5 ug per dose, intramuscular injection</description>
    <arm_group_label>No.2: 2.5 ug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pandemic influenza vaccine (H5N1 strain NIBRG-14)</intervention_name>
    <description>pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 5.0 ug per dose, intramuscular injection</description>
    <arm_group_label>No.3: 5.0 ug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pandemic influenza vaccine (H5N1 strain NIBRG-14)</intervention_name>
    <description>pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection</description>
    <arm_group_label>No. 4: 10 ug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Had received two-dose priming vaccination in previous phase I trial

          -  Be able to show legal identity card for the sake of recruitment

          -  Be able to understand and sign the informed consent.

        Exclusion Criteria:

          -  Womanï¼š Who breast-feeding or planning to become pregnant during the study

          -  Any history of allergic reactions to vaccines or eggs

          -  Autoimmune disease or immunodeficiency

          -  Diabetes mellitus (type I or II), with the exception of gestational diabetes

          -  Serious angioedema episodes within the previous 3 years or requiring medication in the
             previous two years

          -  Hypertension that was not well controlled by medication or is more than 145/95 mmHg at
             enrollment

          -  Active malignancy or treated malignancy for which there is not reasonable assurance of
             sustained cure or malignancy that is likely to recur during the period of study

          -  Guillain-Barre Syndrome

          -  Women subjects with positive urinary pregnancy test

          -  Any history of immunosuppressive medications or cytotoxic medications or inhaled
             corticosteroids within the past six months

          -  History of any blood products administration within 3 months before the dosing

          -  Administration of any other investigational research agents within 30 days before the
             dosing

          -  Administration of any live attenuated vaccine within 30 days before the dosing

          -  Administration of subunit or inactivated vaccines, e.g. pneumococcal vaccine, or
             allergy treatment with antigen injections, within 14 days before the dosing

          -  Be receiving anti-TB prophylaxis or therapy currently

          -  Axillary temperature &gt;37.0 centigrade at the time of dosing

          -  Psychiatric condition that precludes compliance with the protocol; past or present
             psychoses; past or present bipolar disorder requiring therapy that has not been well
             controlled on medication for the past two years; disorder requiring lithium; or
             suicidal ideation occurring within five years prior to enrollment

          -  Any medical, psychiatric, social condition, occupational reason or other
             responsibility that, in the judgment of the investigator, is a contraindication to
             protocol participation or impairs a volunteer's ability to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>61 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2008</study_first_submitted>
  <study_first_submitted_qc>April 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2008</study_first_posted>
  <last_update_submitted>April 16, 2008</last_update_submitted>
  <last_update_submitted_qc>April 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

